Market Summary | Major Indices | Market Movers | Market Sectors | Mutual Funds | A-Z Stock Listings
ETF Screener | World Markets | Currencies | CEO Wealthmeter | Oil / Energy | Metals
Treasury Rates | Calculators | My Watchlist | My Portfolio
         Symbol Lookup
ARYX THERAPEUTICS Add to My Watchlist (NSDQ: ARYX) 
Detailed Quote
News
Chart
SEC Filings
Profile
Historical
Options
     ARYx 2.90 -0.05 (-1.69%) 10,700
6300 Dumbarton Circle
Fremont, CA 94555 US
(510) 585-2200
(510) 585-2202 fax
www.aryx.com
CEO Dr. Paul Goddard, Ph.D.
Auditor Ernst & Young LLP
Exchange Traded NQ
ISIN Number US0433871094
CIK Number 1410064
NAICS Code 325412
Business Summary
A biopharmaceutical Company, focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.AFT.
Number of Employees 75
Share Fundamentals
Market Cap 80.00M
Shares Outstanding 27.59M
Float 26.78M
Short Interest 899.62K
Financial Strength
Revenue (TTM) N/A
Earnings (TTM) -$40,429,000
Quick Ratio 1.4:1
Current Ratio 1.5:1
Total Debt/Equity 7.88:1
Profitability
Gross Margin N/A
EBITDA Margin N/A
Profit Margin N/A
Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Market News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs